Promotion of angiogenesis by sustained release of rhGM-CSF from heparinized collagen/chitosan scaffolds

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 100 B, Issue 3, 2012, Pages 788-798

  Sun, Huafeng ^a,b   Wang, Xingang ^a   Hu, Xinlei ^a   Yu, Weijie ^c   You, Chuangang ^a   Hu, Hang ^a   Han, Chunmao ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b The 117th Hospital of Chinese PLA   (China)

^c Department of General Surgery   (China)

Author keywords

collagen; neovascularization; recombinant human granulocyte macrophage colony stimulating factor (rhGM CSF); skin tissue engineering; sustained release

Indexed keywords

ANGIOGENESIS; CELLULAR ADHESION; COMPOSITE SCAFFOLDS; DERMAL SUBSTITUTES; FOUR-GROUP; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTORS; IN-VITRO; IN-VIVO; NEOVASCULARIZATION; PHYSICOCHEMICAL PROPERTY; RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (RHGM-CSF); RELEASE PATTERN; SKIN DEFECTS; SKIN TISSUE ENGINEERING; SUSTAINED RELEASE; THERAPEUTIC AGENTS; TIME POINTS; TISSUE SPECIMENS; VESSEL FORMATION; WESTERN BLOTTING;

ADHESION; BIODEGRADATION; COLLAGEN; DEFECTS; MACROPHAGES; TISSUE;

SCAFFOLDS (BIOLOGY);

CHITOSAN; COLLAGEN; HEPARIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPARINIZATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MALE; NANOFABRICATION; NONHUMAN; PROTEIN EXPRESSION; RAT; SCANNING ELECTRON MICROSCOPY; WESTERN BLOTTING;

ABSORBABLE IMPLANTS; ANIMALS; CHITOSAN; COLLAGEN; DELAYED-ACTION PREPARATIONS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEPARIN; HUMANS; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; SKIN; TISSUE SCAFFOLDS; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84858069989     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.32512     Document Type: Article

References (65)

1. Singer AJ, Clark RA,. Cutaneous wound healing. N Engl J Med 1999; 341: 738-746. (Pubitemid 29407375)
2. Hrabchak C, Flynn L, Woodhouse KA,. Biological skin substitutes for wound cover and closure. Expert Rev Med Devices 2006; 3: 373-385.
3. Balasubramani M, Kumar TR, Babu M,. Skin substitutes: A review. Burns 2001; 27: 534-544. (Pubitemid 32655019)
4. Guo R, Xu S, Ma L, Huang A, Gao C,. Enhanced angiogenesis of gene-activated dermal equivalent for treatment of full thickness incisional wounds in a porcine model. Biomaterials 2010; 31: 7308-7320.
5. Pieper JS, Hafmans T, van Wachem PB, van Luyn MJ, Brouwer LA, Veerkamp JH, van Kuppevelt TH,. Loading of collagen-heparan sulfate matrices with bFGF promotes angiogenesis and tissue generation in rats. J Biomed Mater Res 2002; 62: 185-194. (Pubitemid 34988495)
6. Mooney DJ, Mikos AG,. Growing new organs. Sci Am 1999; 280: 60-65.
7. Egana JT, Fierro FA, Kruger S, Bornhauser M, Huss R, Lavandero S, Machens HG,. Use of human mesenchymal cells to improve vascularization in a mouse model for scaffold-based dermal regeneration. Tissue Eng Part A 2009; 15: 1191-1200.
8. Guo R, Xu S, Ma L, Huang A, Gao C,. The healing of full-thickness burns treated by using plasmid DNA encoding VEGF-165 activated collagen-chitosan dermal equivalents. Biomaterials 2011; 32: 1019-1031.
9. Hughes GC, Biswas SS, Yin B, Coleman RE, DeGrado TR, Landolfo CK, Lowe JE, Annex BH, Landolfo KP,. Therapeutic angiogenesis in chronically ischemic porcine myocardium: Comparative effects of bFGF and VEGF. Ann Thorac Surg 2004; 77: 812-818. (Pubitemid 38292073)
10. Nazhat SN, Neel EA, Kidane A, Ahmed I, Hope C, Kershaw M, Lee PD, Stride E, Saffari N, Knowles JC, Brown RA,. Controlled microchannelling in dense collagen scaffolds by soluble phosphate glass fibers. Biomacromolecules 2007; 8: 543-551. (Pubitemid 46323271)
11. Borselli C, Oliviero O, Battista S, Ambrosio L, Netti PA,. Induction of directional sprouting angiogenesis by matrix gradients. J Biomed Mater Res A 2007; 80: 297-305. (Pubitemid 46127394)
12. Wissink MJ, Beernink R, Scharenborg NM, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J,. Endothelial cell seeding of (heparinized) collagen matrices: Effects of bFGF pre-loading on proliferation (after low density seeding) and pro-coagulant factors. J Control Release 2000; 67: 141-155. (Pubitemid 30303830)
13. Nillesen ST, Geutjes PJ, Wismans R, Schalkwijk J, Daamen WF, van Kuppevelt TH,. Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF2 and VEGF. Biomaterials 2007; 28: 1123-1131. (Pubitemid 44809425)
14. Sun B, Chen B, Zhao Y, Sun W, Chen K, Zhang J, Wei Z, Xiao Z, Dai J,. Crosslinking heparin to collagen scaffolds for the delivery of human platelet-derived growth factor. J Biomed Mater Res B Appl Biomater 2009; 91: 366-372.
15. Smith JD, Melhem ME, Magge KT, Waggoner AS, Campbell PG,. Improved growth factor directed vascularization into fibrin constructs through inclusion of additional extracellular molecules. Microvasc Res 2007; 73: 84-94. (Pubitemid 46241228)
16. Chen RR, Mooney DJ,. Polymeric growth factor delivery strategies for tissue engineering. Pharm Res 2003; 20: 1103-1112. (Pubitemid 36951832)
17. Yao C, Roderfeld M, Rath T, Roeb E, Bernhagen J, Steffens G,. The impact of proteinase-induced matrix degradation on the release of VEGF from heparinized collagen matrices. Biomaterials 2006; 27: 1608-1616. (Pubitemid 41739586)
18. Steffens GC, Yao C, Prevel P, Markowicz M, Schenck P, Noah EM, Pallua N,. Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with vascular endothelial growth factor. Tissue Eng 2004; 10: 1502-1509. (Pubitemid 39557853)
19. Wissink MJ, Beernink R, Pieper JS, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J,. Immobilization of heparin to EDC/NHS-crosslinked collagen. Characterization and in vitro evaluation. Biomaterials 2001; 22: 151-163.
20. Shi H, Han C, Mao Z, Ma L, Gao C,. Enhanced angiogenesis in porous collagen-chitosan scaffolds loaded with angiogenin. Tissue Eng Part A 2008; 14: 1775-1785.
21. Brown CD, Kreilgaard L, Nakakura M, Caram-Lelham N, Pettit DK, Gombotz WR, Hoffman AS,. Release of PEGylated granulocyte-macrophage colony-stimulating factor from chitosan/glycerol films. J Control Release 2001; 72: 35-46. (Pubitemid 32522342)
22. Middleton M, Thatcher N,. G- and GM-CSF. Int J Antimicrob Agents 1998; 10: 91-93. (Pubitemid 28334190)
23. Kondo M, Scherer DC, Miyamoto T, King AG, Akashi K, Sugamura K, Weissman IL,. Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines. Nature 2000; 407: 383-386.
24. Miller G, Pillarisetty VG, Shah AB, Lahrs S, Xing Z, DeMatteo RP,. Endogenous granulocyte-macrophage colony-stimulating factor overexpression in vivo results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function. J Immunol 2002; 169: 2875-2885. (Pubitemid 35013128)
25. Krakowski M, Abdelmalik R, Mocnik L, Krahl T, Sarvetnick N,. Granulocyte macrophage-colony stimulating factor (GM-CSF) recruits immune cells to the pancreas and delays STZ-induced diabetes. J Pathol 2002; 196: 103-112.
26. Bussolino F, Ziche M, Wang JM, Alessi D, Morbidelli L, Cremona O, Bosia A, Marchisio PC, Mantovani A,. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest 1991; 87: 986-995.
27. Imokawa G, Yada Y, Kimura M, Morisaki N,. Granulocyte/macrophage colony-stimulating factor is an intrinsic keratinocyte-derived growth factor for human melanocytes in UVA-induced melanosis. Biochem J 1996; 313 (Part 2): 625-631. (Pubitemid 26030157)
28. Fang Y, Gong SJ, Xu YH, Hambly BD, Bao S,. Impaired cutaneous wound healing in granulocyte/macrophage colony-stimulating factor knockout mice. Br J Dermatol 2007; 157: 458-465. (Pubitemid 47256111)
29. Payne WG, Ochs DE, Meltzer DD, Hill DP, Mannari RJ, Robson LE, Robson MC,. Long-term outcome study of growth factor-treated pressure ulcers. Am J Surg 2001; 181: 81-86. (Pubitemid 32209128)
30. Robson MC, Hill DP, Smith PD, Wang X, Meyer-Siegler K, Ko F, VandeBerg JS, Payne WG, Ochs D, Robson LE,. Sequential cytokine therapy for pressure ulcers: Clinical and mechanistic response. Ann Surg 2000; 231: 600-611. (Pubitemid 30185868)
31. Marques da Costa R, Jesus FM, Aniceto C, Mendes M,. Double-blind randomized placebo-controlled trial of the use of granulocyte-macrophage colony-stimulating factor in chronic leg ulcers. Am J Surg 1997; 173: 165-168. (Pubitemid 27163841)
32. Zhang L, Chen J, Han C,. A multicenter clinical trial of recombinant human GM-CSF hydrogel for the treatment of deep second-degree burns. Wound Repair Regen 2009; 17: 685-689.
33. Wang ZY, Zhang Q, Liao ZJ, Han CM, Lv GZ, Luo CQ, Chen J, Yang SX, Yang XD, Liu Q,. [Effect of recombinant human granulocyte-macrophage colony stimulating factor on wound healing in patients with deep partial thickness burn]. Zhonghua Shao Shang Za Zhi 2008; 24: 107-110. (Pubitemid 351662886)
34. Hu X, Sun H, Han C, Wang X, Yu W,. Topically applied rhGM-CSF for the wound healing: A systematic review. Burns 2011; 37: 729-741.
35. Ma L, Gao C, Mao Z, Zhou J, Shen J, Hu X, Han C,. Collagen/chitosan porous scaffolds with improved biostability for skin tissue engineering. Biomaterials 2003; 24: 4833-4841. (Pubitemid 37188662)
36. Yannas IV, Lee E, Orgill DP, Skrabut EM, Murphy GF,. Synthesis and characterization of a model extracellular matrix that induces partial regeneration of adult mammalian skin. Proc Natl Acad Sci U S A 1989; 86: 933-937. (Pubitemid 19056266)
37. O'Brien FJ, Harley BA, Yannas IV, Gibson LJ,. The effect of pore size on cell adhesion in collagen-GAG scaffolds. Biomaterials 2005; 26: 433-441. (Pubitemid 38951110)
38. Ma L, Gao C, Mao Z, Shen J, Hu X, Han C,. Thermal dehydration treatment and glutaraldehyde cross-linking to increase the biostability of collagen-chitosan porous scaffolds used as dermal equivalent. J Biomater Sci Polym Ed 2003; 14: 861-874. (Pubitemid 37160564)
39. Hinrichs WLJ, tenHoopen HWM, Wissink MJB, Engbers GHM, Feijen J,. Design of a new type of coating for the controlled release of heparin. J Control Release 1997; 45: 163-176. (Pubitemid 27065218)
40. Gilles MA, Hudson AQ, Borders CL Jr,. Stability of water-soluble carbodiimides in aqueous solution. Anal Biochem 1990; 184: 244-248. (Pubitemid 20055618)
41. Wissink MJ, Beernink R, Pieper JS, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J,. Binding and release of basic fibroblast growth factor from heparinized collagen matrices. Biomaterials 2001; 22: 2291-2299. (Pubitemid 32591363)
42. Smith PK, Mallia AK, Hermanson GT,. Colorimetric method for the assay of heparin content in immobilized heparin preparations. Anal Biochem 1980; 109: 466-473. (Pubitemid 11101298)
43. Sano S, Kato K, Ikada Y,. Introduction of functional groups onto the surface of polyethylene for protein immobilization. Biomaterials 1993; 14: 817-822. (Pubitemid 23272147)
44. Konas E, Canter HI, Korkusuz P, Demir D, Oner F, Mavili ME,. A new concept in the treatment of extravasation injury: Controlled drug delivery systems. J BUON 2010; 15: 592-600.
45. Grzybowski J, Oldak E, Antos-Bielska M, Janiak MK, Pojda Z,. New cytokine dressings. I. Kinetics of the in vitro rhG-CSF, rhGM-CSF, and rhEGF release from the dressings. Int J Pharm 1999; 184: 173-178. (Pubitemid 29317650)
46. Wissink MJ, van Luyn MJ, Beernink R, Dijk F, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J,. Endothelial cell seeding on crosslinked collagen: Effects of crosslinking on endothelial cell proliferation and functional parameters. Thromb Haemost 2000; 84: 325-331. (Pubitemid 30601482)
47. van Wachem PB, Plantinga JA, Wissink MJ, Beernink R, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J, van Luyn MJ,. In vivo biocompatibility of carbodiimide-crosslinked collagen matrices: Effects of crosslink density, heparin immobilization, and bFGF loading. J Biomed Mater Res 2001; 55: 368-378. (Pubitemid 32240173)
48. Kanzler MH, Gorsulowsky DC, Swanson NA,. Basic mechanisms in the healing cutaneous wound. J Dermatol Surg Oncol 1986; 12: 1156-1164. (Pubitemid 17182079)
49. Martin P,. Wound healing€"Aiming for perfect skin regeneration. Science 1997; 276: 75-81. (Pubitemid 27161246)
50. Diegelmann RF, Evans MC,. Wound healing: An overview of acute, fibrotic and delayed healing. Front Biosci 2004; 9: 283-289. (Pubitemid 38925460)
51. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE,. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001; 70: 1-20. (Pubitemid 32144788)
52. Liang A, Du Y, Wang K, Lin B,. Quantitative investigation of the interaction between granulocyte-macrophage colony-stimulating factor and heparin by capillary zone electrophoresis. J Sep Sci 2006; 29: 1637-1641. (Pubitemid 44184061)
53. Sebollela A, Cagliari TC, Limaverde GS, Chapeaurouge A, Sorgine MH, Coelho-Sampaio T, Ramos CH, Ferreira ST,. Heparin-binding sites in granulocyte-macrophage colony-stimulating factor. Localization and regulation by histidine ionization. J Biol Chem 2005; 280: 31949-31956. (Pubitemid 41291945)
54. Modrowski D, Basle M, Lomri A, Marie PJ,. Syndecan-2 is involved in the mitogenic activity and signaling of granulocyte-macrophage colony-stimulating factor in osteoblasts. J Biol Chem 2000; 275: 9178-9185. (Pubitemid 30185134)
55. Modrowski D, Lomri A, Marie PJ,. Glycosaminoglycans bind granulocyte-macrophage colony-stimulating factor and modulate its mitogenic activity and signaling in human osteoblastic cells. J Cell Physiol 1998; 177: 187-195. (Pubitemid 28421534)
56. Alvarez-Silva M, Borojevic R,. GM-CSF and IL-3 activities in schistosomal liver granulomas are controlled by stroma-associated heparan sulfate proteoglycans. J Leukoc Biol 1996; 59: 435-441. (Pubitemid 26139827)
57. Alvarez-Silva M, da Silva LC, Borojevic R,. Cell membrane-associated proteoglycans mediate extramedullar myeloid proliferation in granulomatous inflammatory reactions to schistosome eggs. J Cell Sci 1993; 104 (Part 2): 477-484. (Pubitemid 23098686)
58. Leibovich SJ, Ross R,. The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am J Pathol 1975; 78: 71-100.
59. Gasson JC,. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991; 77: 1131-1145.
60. Breuhahn K, Mann A, Muller G, Wilhelmi A, Schirmacher P, Enk A, Blessing M,. Epidermal overexpression of granulocyte-macrophage colony-stimulating factor induces both keratinocyte proliferation and apoptosis. Cell Growth Differ 2000; 11: 111-121. (Pubitemid 30131491)
61. Mann A, Breuhahn K, Schirmacher P, Blessing M,. Keratinocyte-derived granulocyte-macrophage colony stimulating factor accelerates wound healing: Stimulation of keratinocyte proliferation, granulation tissue formation, and vascularization. J Invest Dermatol 2001; 117: 1382-1390. (Pubitemid 34032763)
62. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M,. Growth factors and cytokines in wound healing. Wound Repair Regen 2008; 16: 585-601.
63. Goldberg MT, Han YP, Yan C, Shaw MC, Garner WL,. TNF-alpha suppresses alpha-smooth muscle actin expression in human dermal fibroblasts: an implication for abnormal wound healing. J Invest Dermatol 2007; 127: 2645-2655. (Pubitemid 47585056)
64. Riedel K, Riedel F, Goessler UR, Germann G, Sauerbier M,. Tgf-beta antisense therapy increases angiogenic potential in human keratinocytes in vitro. Arch Med Res 2007; 38: 45-51. (Pubitemid 44914018)
65. Carmeliet P,. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-395. (Pubitemid 30208155)